

Nicolas Goossens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6557963/publications.pdf>

Version: 2024-02-01

72
papers

3,731
citations

201575

27
h-index

133188

59
g-index

78
all docs

78
docs citations

78
times ranked

6800
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. <i>Journal of Hepatology</i> , 2018, 68, 526-549.	1.8	506
2	Cancer biomarker discovery and validation. <i>Translational Cancer Research</i> , 2015, 4, 256-269.	0.4	354
3	A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. <i>Journal of Hepatology</i> , 2018, 69, 385-395.	1.8	330
4	Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. <i>Nature Immunology</i> , 2015, 16, 1235-1244.	7.0	278
5	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	7.7	172
6	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. <i>Hepatology</i> , 2012, 55, 384-394.	3.6	138
7	Hepatitis C virus-induced hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 105.	4.5	127
8	Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e101.	1.3	124
9	Is genotype 3 of the hepatitis C virus the new villain?. <i>Hepatology</i> , 2014, 59, 2403-2412.	3.6	116
10	Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. <i>Nature Communications</i> , 2018, 9, 4962.	5.8	111
11	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. <i>Gut</i> , 2016, 65, 1754-1764.	6.1	108
12	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). <i>Journal of Hepatology</i> , 2021, 75, 610-622.	1.8	96
13	Molecular classification of hepatocellular carcinoma: potential therapeutic implications. <i>Hepatic Oncology</i> , 2015, 2, 371-379.	4.2	95
14	Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. <i>Journal of Hepatology</i> , 2020, 73, 533-539.	1.8	94
15	Clinicopathological indices to predict hepatocellular carcinoma molecular classification. <i>Liver International</i> , 2016, 36, 108-118.	1.9	93
16	The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy. <i>Scientific Reports</i> , 2016, 6, 39342.	1.6	77
17	Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. <i>Experimental and Molecular Medicine</i> , 2017, 49, e396-e396.	3.2	61
18	Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. <i>Gastroenterology</i> , 2017, 152, 53-67.e3.	0.6	61

#	ARTICLE	IF	CITATIONS
19	Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis. <i>Journal of Hepatology</i> , 2015, 63, 609-621.	1.8	59
20	NAFLD and MAFLD as emerging causes of HCC: A populational study. <i>JHEP Reports</i> , 2021, 3, 100231.	2.6	54
21	Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1619-1628.	2.4	47
22	Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis. <i>Gastroenterology</i> , 2018, 154, 965-975.	0.6	41
23	Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance. <i>Nature Communications</i> , 2017, 8, 1820.	5.8	40
24	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	40
25	Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. <i>Journal of Advanced Research</i> , 2017, 8, 149-159.	4.4	39
26	Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. <i>Scientific Reports</i> , 2017, 7, 42563.	1.6	29
27	Use of big data in drug development for precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 245-253.	0.4	28
28	Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. <i>Hepatology</i> , 2017, 66, 1344-1346.	3.6	28
29	Activation of the oncogenic miR-21 promotes HCV replication and steatosis induced by the viral core 3a protein. <i>Liver International</i> , 2019, 39, 1226-1236.	1.9	24
30	The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2014, 18, 147-156.	1.0	23
31	Cardiovascular Manifestations of Hepatitis C Virus. <i>Clinics in Liver Disease</i> , 2017, 21, 465-473.	1.0	23
32	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. <i>Nature Communications</i> , 2021, 12, 5525.	5.8	21
33	Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated?. <i>Current Hepatology Reports</i> , 2017, 16, 64-71.	0.4	17
34	Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection. <i>Reviews on Recent Clinical Trials</i> , 2015, 9, 204-209.	0.4	17
35	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. <i>Gastroenterology</i> , 2022, 162, 1210-1225.	0.6	17
36	Drug Pricing Evolution in Hepatitis C. <i>PLoS ONE</i> , 2016, 11, e0157098.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease. <i>World Journal of Hepatology</i> , 2018, 10, 73-81.	0.8	14
38	Severe immune-mediated drug-induced liver injury linked to ibandronate: A case report. <i>Journal of Hepatology</i> , 2013, 59, 1139-1142.	1.8	13
39	Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?. <i>Gastroenterology</i> , 2016, 150, 1710-1717.	0.6	13
40	Molecular prognostic prediction in liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 10262.	1.4	12
41	Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2017, 9, 1077.	1.7	12
42	Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 317-325.	1.7	12
43	Gene signature and MELD score and alcohol relapse determine long-term prognosis of patients with severe alcoholic hepatitis. <i>Liver International</i> , 2020, 40, 565-570.	1.9	12
44	Nonalcoholic fatty liver disease burden in Switzerland 2018-2030. <i>Swiss Medical Weekly</i> , 2019, 149, w20152.	0.8	12
45	Use of glasgow-blatchford bleeding score reduces hospital stay duration and costs for patients with low-risk upper GI bleeding. <i>Endoscopy International Open</i> , 2014, 02, E74-E79.	0.9	11
46	A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 967-974.	0.8	11
47	Endovascular Treatment of Arterial Complications After Liver Transplantation: Long-Term Follow-Up Evaluated on Doppler Ultrasound and Magnetic Resonance Cholangiopancreatography. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 381-388.	0.9	11
48	Recent advances in gastrointestinal cancers. <i>World Journal of Gastroenterology</i> , 2021, 27, 4493-4503.	1.4	11
49	DOME/GALT type adenocarcinoma of the colon: a case report, literature review and a unified phenotypic categorization. <i>Diagnostic Pathology</i> , 2015, 10, 92.	0.9	8
50	Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2021, 11, 20827.	1.6	7
51	Origin and interpretation of cancer transcriptome profiling: the essential role of the stroma in determining prognosis and drug resistance. <i>EMBO Molecular Medicine</i> , 2015, 7, 1385-1387.	3.3	6
52	Novel substituted aminothiazoles as potent and selective anti-hepatocellular carcinoma agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5819-5824.	1.0	6
53	Peribiliary Gland Dilatation in Cirrhosis: Relationship with Liver Failure and Stem Cell/Proliferation Markers. <i>Digestive Diseases and Sciences</i> , 2017, 62, 699-707.	1.1	6
54	Tolerogenic properties of liver macrophages in non-alcoholic steatohepatitis. <i>Liver International</i> , 2020, 40, 609-621.	1.9	6

#	ARTICLE	IF	CITATIONS
55	Clinical Presentation and Gene Expression of Acute Alcohol-Induced Microvesicular Steatosis Mimicking Alcoholic Hepatitis. <i>Hepatology Communications</i> , 2021, 5, 618-628.	2.0	6
56	Impact of Maternal Obesity on Liver Disease in the Offspring: A Comprehensive Transcriptomic Analysis and Confirmation of Results in a Murine Model. <i>Biomedicines</i> , 2022, 10, 294.	1.4	6
57	Digital clubbing in association with hepatopulmonary syndrome. <i>Hepatology</i> , 2011, 53, 365-366.	3.6	5
58	Liver volume is a prognostic indicator for clinical outcome of patients with alcoholic hepatitis. <i>Abdominal Radiology</i> , 2017, 42, 460-467.	1.0	5
59	Personalized management of hepatocellular carcinoma based on molecular information: Future prospects. <i>Clinical Liver Disease</i> , 2015, 5, 132-135.	1.0	4
60	Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. <i>Journal of Viral Hepatitis</i> , 2018, 25, 920-929.	1.0	3
61	Management of hepatocellular carcinoma: SASL expert opinion statement. <i>Swiss Medical Weekly</i> , 2020, 150, w20296.	0.8	3
62	NAFLD is a rising cause of HCC in women in a prospective populational cohort spanning 24 years (1990-2014). <i>Journal of Hepatology</i> , 2020, 73, S160-S161.	1.8	1
63	Autologous hematopoietic stem cell transplantation into the liver: impact on hepatic macrophagic expansion and gene expression. <i>Journal of Hepatology</i> , 2017, 66, S351.	1.8	0
64	Mortality in Bariatric Surgery. , 2017, , 207-216.		0
65	THU-203-Hepatitis D infection and risk of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. <i>Journal of Hepatology</i> , 2019, 70, e252-e253.	1.8	0
66	A human liver cell-based system modeling a clinical prognostic liver signature combined with single cell RNA-seq for discovery of novel liver disease therapeutics. <i>Journal of Hepatology</i> , 2020, 73, S28-S29.	1.8	0
67	Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma"; <i>Journal of Hepatology</i> , 2020, 73, 1585-1586.	1.8	0
68	Management of Acute Wilsonian Hepatitis with Severe Hemolysis: A Successful Combination of Chelation and MARS Dialysis. <i>Case Reports in Hepatology</i> , 2021, 2021, 1-6.	0.4	0
69	COVID-19-related abdominal pain is associated with elevated liver transaminases, which could predict poor clinical outcomes. <i>British Journal of Surgery</i> , 2021, 108, .	0.1	0
70	Use of induction therapy in pediatric heart transplant recipients in Switzerland " Analysis of the Swiss national database. <i>Transplant Immunology</i> , 2021, 68, 101443.	0.6	0
71	Non-invasive diagnosis of liver steatosis: ready for primetime?. <i>Swiss Medical Weekly</i> , 2019, 149, w20108.	0.8	0
72	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0